Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +11.39%
#3 Meteora Meteora +10.48%
#4 Pump.fun Pump.fun +10.28%
#5 Unit Pump Unit Pump +10.23%
#6 eCash eCash +8.55%
#7 Cash Cat Cash Cat +8.41%
#8 OPENLOOT OPENLOOT +8.41%
#9 Glidr Glidr +7.60%
#10 Fake World Assets Fake World Assets +6.63%
Coin of the day
PulseChain PulseChain
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rankning i aktier #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Aktiekurs
$0.55
Senast synkroniserad: 2025-02-11
Marknadsvärde
$28.90M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Kategori

Healthcare
Intäkter för Marinus Pharmaceuticals, Inc. (MRNS)
Intäkter i Sep 2024 TTM: $31.47M
Enligt Marinus Pharmaceuticals, Inc. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $31.47M. År 2022 hade företaget intäkter på $25.48M en ökning jämfört med intäkterna år 2021, som var $15.35M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för Marinus Pharmaceuticals, Inc. från 2012 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH